SILO (Silo Pharma, Inc.) שווי פעילות לרווח לפני ריבית, מסים ופחת

Silo Pharma, Inc. (SILO) delegates its entire production cycle and testing to external contractors, relying fully on third-party vendors. This chart of EV/EBITDA metrics is fixed at 0.00, while management develops microdosing for the treatment of inflammation and neurology. The business relies on venture capital and clinical trials against Alzheimer's, ignoring general market trends.

Identifying assets with high fundamental resilience requires analyzing the total enterprise value relative to its operating profit before taxes, depreciation, and amortization. This metric compares market capitalization, adjusted for net debt, against actual cash flow to identify company undervaluation. For Silo Pharma, Inc. (SILO), which optimizes R&D through university outsourcing, the EV/EBITDA valuation multiple reflects the efficiency of this capital expenditure reduction model.